Elanco Animal Health (NYSE:ELAN) Hits New 12-Month High – What’s Next?

Elanco Animal Health Incorporated (NYSE:ELAN) hit a new 52-week high on Monday . The stock traded as high as $23.90 and last traded at $23.8480, with a volume of 4648597 shares changing hands. The stock had previously closed at $23.47.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ELAN shares. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Wednesday, November 19th. UBS Group upped their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.78.

Elanco Animal Health Price Performance

The business’s 50-day moving average price is $22.29 and its 200 day moving average price is $19.42. The company has a market capitalization of $11.85 billion, a P/E ratio of 397.53, a price-to-earnings-growth ratio of 3.26 and a beta of 1.87. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $21.64 per share, with a total value of $150,398.00. Following the completion of the acquisition, the chief financial officer owned 124,233 shares of the company’s stock, valued at $2,688,402.12. This trade represents a 5.93% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the transaction, the director owned 131,773 shares of the company’s stock, valued at $2,806,764.90. The trade was a 8.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 43,450 shares of company stock valued at $937,883 over the last 90 days. 0.89% of the stock is owned by insiders.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC increased its holdings in shares of Elanco Animal Health by 13.7% in the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after buying an additional 718 shares during the last quarter. Jones Financial Companies Lllp grew its position in Elanco Animal Health by 15.2% in the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after acquiring an additional 798 shares in the last quarter. MTM Investment Management LLC increased its stake in Elanco Animal Health by 5.5% in the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock valued at $218,000 after acquiring an additional 800 shares during the last quarter. US Bancorp DE raised its position in Elanco Animal Health by 1.9% during the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after purchasing an additional 824 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.